目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
2.3 GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 HUMAN MICROBIOME MARKET OVERVIEW
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE AND COUNTRY, 2024
4.3 HUMAN MICROBIOME MARKET, BY TYPE, 2025 VS. 2031
4.4 HUMAN MICROBIOME MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.5 HUMAN MICROBIOME MARKET, BY END USER, 2025

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Collaborative initiatives between organizations and academia
5.2.1.2 Increasing number of startups/SMEs exploring microbiome
5.2.1.3 Advancements in microbiome sequencing
5.2.2 RESTRAINTS
5.2.2.1 Complex regulatory policies
5.2.2.2 High investments in commercializing microbiome drugs
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for personalized medicines
5.2.3.2 Emergence of postbiotics
5.2.4 CHALLENGES
5.2.4.1 Slow patient adoption of microbiome-based therapies
5.2.4.2 Complexities in developing microbiome therapies
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.3.1 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
5.3.1.1 Market readiness
5.3.1.2 Adoption
5.3.1.3 Maturity
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
5.4.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022-2024
5.5 VALUE CHAIN ANALYSIS
5.5.1 HUMAN MICROBIOME DRUGS
5.5.2 HUMAN MICROBIOME SUPPLEMENTS
5.5.3 HUMAN MICROBIOME DIAGNOSTICS
5.6 ECOSYSTEM ANALYSIS
5.6.1 ECOSYSTEM SHIFT
5.6.1.1 Specialized raw material and data suppliers
5.6.1.2 Hot-bet innovator startups
5.6.1.3 Integrated end users and prosumer models
5.6.1.4 Regulatory and quality assurance orchestrators
5.6.1.5 Diagnostics-driven personalization
5.6.1.6 Microbiome-as-a-Service (Maas)
5.6.2 EMERGING BUSINESS MODELS
5.6.2.1 Emerging B2C model
5.6.2.2 Personalized supplements model
5.6.3 INTERCONNECTED MARKET DYNAMICS
5.7 INVESTMENT AND FUNDING SCENARIO
5.7.1 MAJOR INVESTMENTS AND FUNDING BY KEY MARKET PLAYERS
5.7.2 OTHER INVESTMENTS AND FUNDING
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Whole-genome sequencing
5.8.1.2 16s RNA sequencing method
5.8.1.3 Nanopore sequencing
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 Metatranscriptomics
5.8.2.2 Metagenomics
5.8.2.3 Metabolomics
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Sample preparation
5.8.3.2 Data analysis
5.8.3.3 Library synthesis
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS, 2025-2026
5.11 CASE STUDY ANALYSIS
5.11.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
5.11.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION
5.11.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS
5.12 TARIFF AND REGULATORY ANALYSIS
5.12.1 TARIFF DATA (HS CODE 3002.90)
5.12.2 REGULATORY LANDSCAPE
5.12.2.1 North America
5.12.2.1.1 US
5.12.2.1.2 Canada
5.12.2.2 Europe
5.12.2.2.1 UK
5.12.2.3 Asia Pacific
5.12.2.3.1 China
5.12.2.3.2 Japan
5.12.2.3.3 South Korea
5.12.2.3.4 Australia
5.12.2.3.5 Rest of Asia Pacific
5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 PIPELINE ANALYSIS
5.16 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL OF AI IN HUMAN MICROBIOME MARKET
5.16.3 AI USE CASES
5.16.4 KEY PLAYERS IMPLEMENTING AI
5.16.5 FUTURE OF GENERATIVE AI IN HUMAN MICROBIOME MARKET
5.17 IMPACT OF US TARIFF ON HUMAN MICROBIOME MARKET
5.17.1 KEY TARIFF RATES
5.17.2 PRICE IMPACT ANALYSIS
5.17.3 KEY IMPACT ON COUNTRY/REGION
5.17.3.1 US
5.17.3.2 Europe
5.17.3.3 Asia Pacific
5.17.3.4 Rest of the World
5.17.4 IMPACT ON END-USE INDUSTRY
5.17.4.1 Hospitals and clinics
5.17.4.2 Long-term care facilities
5.18 MANAGING GLP-1 SIDE EFFECTS WITH MICROBIOME INTERVENTIONS
5.19 FUTURE TRENDS IN HUMAN MICROBIOME MARKET
5.19.1 TYPE
5.19.2 DISEASE
5.19.3 END USER

6 HUMAN MICROBIOME MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 DRUGS
6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET
6.3 SUPPLEMENTS
6.3.1 PROBIOTICS
6.3.1.1 Increasing consumer awareness about probiotics for improved gut health and immunity to aid growth
6.3.2 PREBIOTICS
6.3.2.1 Rising development of targeted prebiotics to expedite growth
6.3.3 SYNBIOTICS
6.3.3.1 Growing demand for personalized treatment and rising incidence of dysbiosis to fuel market
6.4 DIAGNOSTICS
6.4.1 INCREASING PRODUCT LAUNCHES AND TECHNOLOGY TRANSFER TO FACILITATE GROWTH

7 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
7.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT GROWTH
7.3 LIVE BACTERIA PRODUCTS (LBP)
7.3.1 INCREASING CONSUMER FOCUS ON PREVENTIVE HEALTH TO AID GROWTH
7.4 OTHER MICROBIOME TYPES

8 HUMAN MICROBIOME MARKET, BY DISEASE
8.1 INTRODUCTION
8.2 INFECTIOUS DISEASES
8.2.1 EMERGENCE OF MULTIDRUG-RESISTANT BACTERIA TO FOSTER GROWTH
8.3 GASTROINTESTINAL DISEASES
8.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO AID GROWTH
8.4 ENDOCRINE & METABOLIC DISORDERS
8.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET
8.5 OTHER DISEASES

9 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION
9.1 INTRODUCTION
9.2 ORAL ROUTE OF ADMINISTRATION
9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO ENCOURAGE GROWTH
9.3 RECTAL ROUTE OF ADMINISTRATION
9.3.1 ABILITY TO RESTORE HEALTHY GUT TO FACILITATE GROWTH

10 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE
10.1 INTRODUCTION
10.2 STRAIN DEVELOPMENT & OPTIMIZATION
10.2.1 RISING DEMAND FOR TARGETED, STRAIN-SPECIFIC MICROBIOME THERAPIES TO BOOST MARKET
10.3 FERMENTATION & DOWNSTREAM PROCESSING
10.3.1 GROWING DEMAND FOR CLINICAL-STAGE BIOTHERAPEUTICS TO DRIVE MARKET
10.4 FORMULATION & FILL/FINISH
10.4.1 INCREASING STUDIES ON LIVE BIOTHERAPEUTIC PRODUCTS TO PROMOTE GROWTH
10.5 OTHER SERVICES

11 HUMAN MICROBIOME MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITALS & CLINICS
11.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT GROWTH
11.3 LONG-TERM CARE FACILITIES
11.3.1 NEED FOR SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
11.4 OTHER END USERS

12 HUMAN MICROBIOME MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Favorable government initiatives and booming diagnostics sector to drive market
12.2.3 CANADA
12.2.3.1 Increasing prevalence of chronic diseases to expedite growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Rapid increase in government and private funding to propel market
12.3.3 UK
12.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth
12.3.4 FRANCE
12.3.4.1 Growing focus on developing new products and services using microbiome data to boost market
12.3.5 ITALY
12.3.5.1 Rise in research activities to encourage growth
12.3.6 SPAIN
12.3.6.1 Favorable microbiome research landscape to support growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Rapidly expanding healthcare industry to accelerate growth
12.4.3 JAPAN
12.4.3.1 Booming geriatric population to contribute to growth
12.4.4 INDIA
12.4.4.1 Increasing number of human microbiome diagnostic companies to augment growth
12.4.5 SOUTH KOREA
12.4.5.1 Booming bio-health market to advance growth
12.4.6 AUSTRALIA
12.4.6.1 Growing number of product approvals to boost markt
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Rising probiotics demand to drive market
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST
12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
12.6.2 GCC COUNTRIES
12.6.2.1 Saudi Arabia
12.6.2.1.1 Growing focus on healthcare infrastructure to fuel market
12.6.2.2 UAE
12.6.2.2.1 Increasing focus on immunotherapy and biotechnology to augment growth
12.6.2.3 Rest of GCC countries
12.6.3 REST OF MIDDLE EAST
12.7 AFRICA
12.7.1 INCREASING STUDIES AND INITIATIVES ON MICROBIOME TO PROMOTE GROWTH
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET
13.3 REVENUE ANALYSIS, 2022-2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY VALUATION AND FINANCIAL METRICS
13.6 BRAND/PRODUCT COMPARISON
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.7.5.1 Company footprint
13.7.5.2 Region footprint
13.7.5.3 Product footprint
13.7.5.4 Type footprint
13.7.5.5 Disease footprint
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
13.8.5.1 Detailed list of key startups/SMEs
13.8.5.2 Competitive benchmarking of key emerging players/startups
13.9 COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES AND APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC.
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Deals
14.1.1.3.2 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 SEED HEALTH, INC.
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Product launches and approvals
14.1.2.3.2 Deals
14.1.2.3.3 Expansions
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 SERES THERAPEUTICS
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches and approvals
14.1.3.3.2 Deals
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 FERRING B.V.
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches and approvals
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 PENDULUM
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 OPTIBIOTIX HEALTH PLC
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches and approvals
14.1.6.3.2 Deals
14.1.7 BIOGAIA
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches and approvals
14.1.7.3.2 Deals
14.1.7.3.3 Expansions
14.1.8 MAAT PHARMA
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.8.3.2 Other developments
14.1.9 MICROBA
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches and approvals
14.1.10 BIOMEBANK
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.10.3.3 Expansions
14.1.11 BIOHM HEALTH
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Deals
14.1.12 ACTIAL FARMACEUTICA SRL
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.13 RESBIOTIC
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches and approvals
14.1.13.3.2 Deals
14.1.13.3.3 Expansions
14.1.14 INFINANT HEALTH INC.
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Deals
14.1.15 EXEGI PHARMA
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.15.3 Recent developments
14.1.15.3.1 Deals
14.1.16 FINCH THERAPEUTICS GROUP, INC.
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Deals
14.1.17 INFANT BACTERIAL THERAPEUTICS AB
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.18 VIOME LIFESCIENCES
14.1.18.1 Business overview
14.1.18.2 Products offered
14.1.18.3 Recent developments
14.1.18.3.1 Product launches and approvals
14.1.19 GENOVA DIAGNOSTICS
14.1.19.1 Business overview
14.1.19.2 Products offered
14.2 OTHER PLAYERS
14.2.1 AOBIOME
14.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
14.2.3 NUBIYOTA
14.2.4 OXTHERA
14.2.5 NEXBIOME
14.2.6 VEDANTA BIOSCIENCES, INC.
14.2.7 ENTEROME
14.2.8 APSEN FARMACEUTICA
14.2.9 METAGEN, INC.
14.2.10 SNIPR BIOME
14.2.11 MIKROBIOMIK
14.2.12 SYNLOGIC
14.2.13 GENETIC ANALYSIS
14.2.14 METABIOMICS
14.2.15 SUN GENOMICS, INC.

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS